Integral photodynamic therapy of superficial bladder tumors with mainly carcinoma in situ

1993 ◽  
Author(s):  
Tadao Uchibayashi ◽  
Haruo Hisazumi
Keyword(s):  
Photodynamic Therapy ◽  
Carcinoma In Situ ◽  
Bladder Tumors

scholarly journals Whole bladder wall photodynamic therapy using a newly designed light-scattering device for superficial multicentric bladder tumors with/without carcinoma in situ of the bladder.

1987 ◽  
Vol 7 (3) ◽  
pp. 135-136
Author(s):  
Tadao Uchibayashi ◽  
Haruo Hisazumi ◽  
Toshimitsu Misaki ◽  
Shinya Mihara ◽  
Toshiyasu Amano ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Light Scattering ◽  
Carcinoma In Situ ◽  
Bladder Wall ◽  
Bladder Tumors

How well do we manage non-muscle invasive bladder tumors? A UK audit of real-life practices

2020 ◽  
Vol 87 (3) ◽  
pp. 142-148
Author(s):  
Petros Sountoulides ◽  
Wilbert Fana Mutomba ◽  
Emmanouil Bouras ◽  
Jieqi Lim ◽  
Andreas Bourdoumis ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Carcinoma In Situ ◽  
Real Life ◽  
Invasive Bladder Cancer ◽  
Detrusor Muscle ◽  
Bladder Tumors ◽  
Recurrence Rates ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Objective: The aim of this study was to assess the quality of TURBT (transurethral resection of bladder tumor) using surrogate parameters and evaluate adherence to the guidelines regarding the management of bladder tumors. Materials and methods: A clinical audit of all new diagnosis of bladder cancer was undertaken from January 2016 to January 2017. A total of 101 new bladder cancer cases were included. Surrogates of TURBT quality including presence of detrusor in the specimen, rate of re-TUR, presence of carcinoma in situ, and 3-month recurrence rates were analyzed. Adherence to guidelines regarding management of non-muscle invasive bladder cancer including time to re-TUR and utilization of single instillation chemotherapy was evaluated. Results: Absence of detrusor muscle in the specimen of the initial TURBT was noted in 22.8% of the cases. The chance of including muscle in the specimen was almost four-fold for tumors larger than 3 cm. A single instillation of intravesical chemotherapy following TURBT was administered in only 40% of eligible patients; 54.3% of patients had a re-TUR, the majority (61.3%) for high-grade non-muscle invasive bladder cancer on initial TURBT. Re-TUR was done on average 10 weeks after initial TURBT. The 3-month recurrence rate was 36.0% with larger tumors (>3 cm) being more prone to early recurrences. Early recurrences were not affected by intravesical instillations with bacillus Calmette–Guérin or mitomycin C although there was a positive association between the presence of carcinoma in situ on initial resection and early recurrences. Discussion and conclusion: One in two patients will have a re-TUR, and approximately one in two patients will have tumor on re-TUR. Single immediate chemotherapy instillations after TURBT are underutilized. The presence of carcinoma in situ on initial TURBT and tumor size were predictors of early recurrences.

Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette–Guérin immunotherapy

2019 ◽  
Vol 145 (8) ◽  
pp. 2131-2140 ◽  
Author(s):  
Sung Jin Kim ◽  
Dalsan You ◽  
In Gab Jeong ◽  
Cheryn Song ◽  
Bumsik Hong ◽  
...  
Keyword(s):  
Carcinoma In Situ ◽  
Bacillus Calmette Guerin ◽  
Bladder Tumors

scholarly journals Whole bladder wall photodynamic therapy for refractory carcinoma in situ of the bladder

1995 ◽  
Vol 71 (3) ◽  
pp. 625-628 ◽  
Author(s):  
T Uchibayashi ◽  
K Koshida ◽  
K Kunimi ◽  
H Hisazumi
Keyword(s):  
Photodynamic Therapy ◽  
Carcinoma In Situ ◽  
Bladder Wall
Sign in / Sign up

Export Citation Format

Share Document